Alentis Therapeutics doses first patient in phase 1/2 clinical trial of ALE.C04

This first-in-human study evaluates the safety, tolerability and efficacy of ALE.C04 as a monotherapy and in combination.Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company within our portfolio…
andy17.11.2023